Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.

Chung TH, Mulligan G, Fonseca R, Chng WJ.

PLoS One. 2013 Jun 20;8(6):e66361. doi: 10.1371/journal.pone.0066361. Print 2013.

2.

Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.

Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4.

PMID:
23291040
3.

Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

Chen MH, Qi C, Reece D, Chang H.

Hum Pathol. 2012 Jun;43(6):858-64. doi: 10.1016/j.humpath.2011.07.013. Epub 2011 Nov 1.

PMID:
22047644
4.

Genomic stratification of multiple myeloma treated with novel agents.

Jiang A, Reece D, Chang H.

Leuk Lymphoma. 2012 Feb;53(2):202-7. doi: 10.3109/10428194.2011.608449. Epub 2011 Sep 19. Review.

PMID:
21823830
5.

Emerging trends in the clinical use of bortezomib in multiple myeloma.

Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K.

Clin Lymphoma Myeloma. 2005 Sep;6(2):84-8. Review.

PMID:
16231845
6.

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group.

Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638.

7.

An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.

Tan D, Teoh G, Lau LC, Lim A, Lim TH, Yap KC, Premalatha P, Lao ZT, Wee N, Choo C, Wee HC, Su S, Lee YS, Lee LH, Hwang W, Goh YT.

Am J Hematol. 2010 Oct;85(10):752-6. doi: 10.1002/ajh.21812.

8.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.

9.

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

Smith D, Armenteros E, Percy L, Kumar M, Lach A, Herledan G, Stubbs M, Downward J, Yong K.

Br J Haematol. 2015 Jun;169(6):905-8. doi: 10.1111/bjh.13258. Epub 2015 Jan 12. No abstract available.

PMID:
25580780
10.

Clinical impact of chromosomal aberrations in multiple myeloma.

Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G.

J Intern Med. 2011 Feb;269(2):137-47. doi: 10.1111/j.1365-2796.2010.02324.x. Epub 2010 Dec 15. Review.

11.

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Küenburg E, Wieser R, Zielinski C, Drach J.

Leukemia. 2007 Jan;21(1):164-8. Epub 2006 Nov 9.

PMID:
17096015
12.

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H.

Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8.

13.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

14.

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A.

J Clin Oncol. 2009 Sep 1;27(25):4197-203. doi: 10.1200/JCO.2008.19.1916. Epub 2009 Jul 27. Erratum in: J Clin Oncol. 2012 Apr 20;30(12):1398.

15.

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

Richardson PG, Mitsiades C, Ghobrial I, Anderson K.

Curr Opin Oncol. 2006 Nov;18(6):598-608. Review.

PMID:
16988581
16.

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L.

Haematologica. 2014 Feb;99(2):353-9. doi: 10.3324/haematol.2013.088211. Epub 2013 Nov 8.

17.

Current multiple myeloma treatment strategies with novel agents: a European perspective.

Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S.

Oncologist. 2010;15(1):6-25. doi: 10.1634/theoncologist.2009-0203. Epub 2010 Jan 19. Review.

18.

Role of bortezomib for the treatment of previously untreated multiple myeloma.

Mateos MV.

Expert Rev Hematol. 2008 Oct;1(1):17-28. doi: 10.1586/17474086.1.1.17.

PMID:
21083004
19.

Bortezomib in multiple myeloma.

Mateos MV, San Miguel JF.

Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. Review.

PMID:
18070714
20.

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P; IFM and MAG groups.

Leukemia. 2010 Mar;24(3):623-8. doi: 10.1038/leu.2009.273. Epub 2010 Jan 14.

PMID:
20072152

Supplemental Content

Support Center